For CRMP5 detection, we found that the commercial CBA was more sensitive than immunohistochemistry and we therefore consider it a valuable add-on for verification of CRMP5 positivity in diagnosis of PNS. This evidence concerns the gene DPYSL5 and paraneoplastic neurologic syndrome.